CSI Market
Sign In | Register

Viridian Therapeutics Inc (VRDN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VRDN Annual Cash Flow →
Quarterly cash flow trends provide additional context on Viridian Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Mar 31 2025) (Dec 31 2024)
Operating Activities
Income-104.90
Depreciation & amortization0.12
Amortization of Other Assets0.00
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation13.39
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest2.34
Non Cash Lease Expense-
Increase Decrease In Unbilled Revenue Related Party-
Capital Expenditures Incurred But Not Yet Paid-
Increase Decrease In Unbilled Revenue-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Increase Decrease In Contract With Customer Asset-
Debt Extinguishment Expense-
Derivative Gain Loss On Derivative Net-7.53
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable4.63
Increase (Decrease) in Accrued Liabilities-23.69
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.33
Other Working Capital0.00
Other Noncash Income (Expense)0.17
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.86
Discontinued operations0.00
Net Cash flow from Operating Activities-119.65
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities168.60
Payments to Acquire Available-for-sale Securities, Debt-91.32
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities77.26
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.36
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments for Debt Issuance Costs Notes Payable-
Payment For Fractional Share Payment Reverse Stock Split-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.36
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-119.68
Total Cash Flow-36.04
4 historic quarters locked

Sign in to unlock the full Viridian Therapeutics Inc cash flow history.

Sign In Create Free Account

About Viridian Therapeutics Inc De Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001590750-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.